Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results

By sjmartinez • July 11, 2023

Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. Nat Med. 2023 Jul 10. doi: 10.1038/s41591-023-02385-6. Epub ahead of print. PMID: 37429923.

Tags: Hematology/Oncology, Publications

Comparison of basic lymphocyte phenotype results between a diagnostic and a research laboratory

Aziz N, LaBelle E, Jamieson BD, Mimiaga MJ, Detels R. Comparison of basic lymphocyte phenotype results between a diagnostic and a research laboratory. Lab Med.[...]

Developing remote patient monitoring infrastructure using commercially available cloud platforms

Cao M, Ramezani R, Katakwar VK, Zhang W, Boda D, Wani M, Naeim A. Developing remote patient monitoring infrastructure using commercially available cloud platforms. Front[...]

INteractive survivorship program to improve health care REsources [INSPIRE]: A study protocol testing a digital intervention with stepped care telehealth to improve outcomes for adolescent and young adult survivors

Yi JC, Ballard S, Walsh C, Friedman DN, Ganz PA, Jacobs LA, Partridge AH, Mitchell SA, Leisenring WM, Syrjala KL, Baker KS. INteractive survivorship program[...]